“The European subsidiary will serve as an impor

“The European subsidiary will serve as an important bridge to international markets, where we are seeing particularly strong partnering interest in Brilacidin across multiple indications, recently reinforced by compelling clinical data from our Phase 2 trials for Inflammatory Bowel Diseases and Oral Mucositis. I feel the public markets have yet to fully appreciate the potential of our clinical assets. My swap of debt for Company stock demonstrates my strong belief in our pipeline and team.”